707 related articles for article (PubMed ID: 25999428)
1. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
2. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.
Xu C; Wan X; Xu L; Weng H; Yan M; Miao M; Sun Y; Xu G; Dooley S; Li Y; Yu C
J Hepatol; 2015 Jun; 62(6):1412-9. PubMed ID: 25623823
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
Ding Y; Sun X; Chen Y; Deng Y; Qian K
Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
[TBL] [Abstract][Full Text] [Related]
5. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
7. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
9. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
10. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Hirai T; Kimura T; Echizen H
Biol Pharm Bull; 2016; 39(6):1013-21. PubMed ID: 27251504
[TBL] [Abstract][Full Text] [Related]
11. Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia.
Yoon IS; Park DH; Ki SH; Cho SS
J Pharm Pharmacol; 2016 Dec; 68(12):1597-1603. PubMed ID: 27696407
[TBL] [Abstract][Full Text] [Related]
12. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Bruce SP
Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Lee HJ; Jeong KH; Kim YG; Moon JY; Lee SH; Ihm CG; Sung JY; Lee TW
Am J Nephrol; 2014; 40(1):56-63. PubMed ID: 25034030
[TBL] [Abstract][Full Text] [Related]
14. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.
Yisireyili M; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Shoaib Hamrah M; Nakayama T; Wu Cheng X; Matsushita T; Nakamura S; Niwa T; Murohara T; Takeshita K
Sci Rep; 2017 Apr; 7(1):1266. PubMed ID: 28455534
[TBL] [Abstract][Full Text] [Related]
16. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
17. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
18. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Kataoka H; Yang K; Rock KL
Eur J Pharmacol; 2015 Jan; 746():174-9. PubMed ID: 25449036
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
[TBL] [Abstract][Full Text] [Related]
20. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
Lü JM; Yao Q; Chen C
Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]